摘要
目的:探讨替雷利珠单抗联合卡培他滨+奥沙利铂(XELOX)方案对晚期胃癌的疗效、肿瘤标志物、血管新生指标的影响。方法:选取2020年10月—2023年6月南京医科大学附属苏州医院肿瘤内科收治的62例晚期胃癌患者,采用随机数字表法分为观察组与对照组,各31例。对照组采用XELOX方案,观察组采用XELOX方案联合替雷利珠单抗,对比分析两组临床疗效、肿瘤标志物、血管新生指标及不良反应发生情况。结果:观察组治疗总有效率高于对照组(P<0.05);化疗后3周,观察组甲胎蛋白(AFP)、癌胚抗原(CEA)、血清糖类抗原72-4(CA72-4)、血清糖类抗原19-9(CA19-9)、血清糖类抗原125(CA125)、血管内皮生长因子(VEGF)、色素上皮衍生因子(PEDF)、血管生成素-2(Ang-2)均低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替雷利珠单抗联合XELOX方案治疗晚期胃癌术后患者的效果优于单独XELOX化疗,并且安全性可控。
Objective:To explore the efficacy of Tislelizumab combined with Capecitabine+Oxaliplatin(XELOX)regimen in advanced gastric cancer and its influence on tumor markers and angiogenesis indicators.Method:A total of 62 patients with advanced gastric cancer admitted to the Department of Oncology of the Affiliated Suzhou Hospital of Nanjing Medical University from October 2020 to June 2023 were selected and randomly divided into observation group and control group by random number table method,with 31 cases in each group.The control group was treated with the XELOX regimen,while the observation group was treated with the XELOX regimen combined with Tislelizumab.The clinical efficacy,tumor markers,angiogenesis indicators and the occurrence of adverse reactions of the two groups were compared and analyzed.Result:The effective rate of treatment in the observation group was higher than that in the control group(P<0.05).Three weeks after chemotherapy,alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),serum carbohydrate antigen 72-4(CA72-4),serum carbohydrate antigen 19-9(CA19-9),serum carbohydrate antigen 125(CA125),vascular endothelial growth factor(VEGF),pigment epithelium-derived factor(PEDF),and angiopoietin-2(Ang-2)in the observation group were all lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The efficacy of Tislelizumab combined with XELOX regimen in treating postoperative patients with advanced gastric cancer is superior to that of XELOX chemotherapy alone,and its safety is controllable.
作者
俞铭扬
张璐瑶
汪丽钰
郭芬
王国强
YU Mingyang;ZHANG Luyao;WANG Liyu;GUO Fen;WANG Guoqiang(Department of Oncology,the Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou 215000,China;不详)
出处
《中国医学创新》
2025年第36期66-70,共5页
Medical Innovation of China
